Elisa Ficarra, Ilaria Iacobucci, Carmen Baldazzi, Giorgia Simonetti, Elisa Zuffa, Emanuela Ottaviani, Jesús M. Hernández, Antonella Padella, Stefania Paolini, Eugenia Franchini, Federica Zanotti, Giovanni Martinelli, Peter Vandenberghe, Anna Maria Ferrari, Samantha Bruno, Marco Sazzini, Torsten Haferlach, Nicoletta Testoni, Gastone Castellani, Marco Manfrini, Annalisa Astolfi, Simona Bernardi, Italo Faria do Valle, Maria Antonella Laginestra, Jan Cools, Maria Chiara Fontana, Cristina Papayannidis, Giovanni Marconi, Eugenio Fonzi, Daniel Remondini, Michele Cavo, Viviana Guadagnuolo, Lars Bullinger, Simonetti, Giorgia, Padella, Antonella, do Valle, Italo Farìa, Fontana, Maria Chiara, Fonzi, Eugenio, Bruno, Samantha, Baldazzi, Carmen, Guadagnuolo, Viviana, Manfrini, Marco, Ferrari, Anna, Paolini, Stefania, Papayannidis, Cristina, Marconi, Giovanni, Franchini, Eugenia, Zuffa, Elisa, Laginestra, Maria Antonella, Zanotti, Federica, Astolfi, Annalisa, Iacobucci, Ilaria, Bernardi, Simona, Sazzini, Marco, Ficarra, Elisa, Hernandez, Jesus Maria, Vandenberghe, Peter, Cools, Jan, Bullinger, Lar, Ottaviani, Emanuela, Testoni, Nicoletta, Cavo, Michele, Haferlach, Torsten, Castellani, Gastone, Remondini, Daniel, and Martinelli, Giovanni
Background Aneuploidy occurs in more than 20% of acute myeloid leukemia (AML) cases and correlates with an adverse prognosis. Methods To understand the molecular bases of aneuploid acute myeloid leukemia (A‐AML), this study examined the genomic profile in 42 A‐AML cases and 35 euploid acute myeloid leukemia (E‐AML) cases. Results A‐AML was characterized by increased genomic complexity based on exonic variants (an average of 26 somatic mutations per sample vs 15 for E‐AML). The integration of exome, copy number, and gene expression data revealed alterations in genes involved in DNA repair (eg, SLX4IP, RINT1, HINT1, and ATR) and the cell cycle (eg, MCM2, MCM4, MCM5, MCM7, MCM8, MCM10, UBE2C, USP37, CK2, CK3, CK4, BUB1B, NUSAP1, and E2F) in A‐AML, which was associated with a 3‐gene signature defined by PLK1 and CDC20 upregulation and RAD50 downregulation and with structural or functional silencing of the p53 transcriptional program. Moreover, A‐AML was enriched for alterations in the protein ubiquitination and degradation pathway (eg, increased levels of UHRF1 and UBE2C and decreased UBA3 expression), response to reactive oxygen species, energy metabolism, and biosynthetic processes, which may help in facing the unbalanced protein load. E‐AML was associated with BCOR/BCORL1 mutations and HOX gene overexpression. Conclusions These findings indicate that aneuploidy‐related and leukemia‐specific alterations cooperate to tolerate an abnormal chromosome number in AML, and they point to the mitotic and protein degradation machineries as potential therapeutic targets., Aneuploid acute myeloid leukemia (A‐AML) is associated with genomic and transcriptional alterations in the cell cycle and protein degradation pathways. The upregulation of PLK1 and CDC20 and the downregulation of RAD50 and of a p53‐related signature are hallmarks of A‐AML.